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Facts and Ideas From Anywhere
BY WILLIAM C. ROBERTS, MD
Microorganisms (viruses, bacteria,
fungi, protozoa) play the survival
game exceedingly well.
Reprinted with permission from Baylor University Medical Center Proceedings 2003;16:131-
134 (http://www. Bay lor Health. com/Proceedings).
t • "die November/December 2002 issue of
World-Watch compared the September
-^- 11 th tragedy with the magnitude of
other deaths (1). In the USA, the numbers of
persons dying or killed each year on average
are as follows: by cigarette smoking, 431,000;
by obesity, 300,000; by alcohol abuse,
110,000; by motor vehicle accidents, 43,000;
by guns, other than war, 34,000; by adverse
reactions to prescription drugs, 32,000; by
suicide, 31,000; by accidental falls, 15,000;
by accidental poisoning, 9000; by aspirin and
nonsteroidal anti inflammatory drugs
(NSAIDs), 8000; by drowning, 4000; by
choking on ingested objects, 3000; and by the
September llth attacks in 2001, 3000.
In other countries, the numbers of people
dying or killed each year on average are as
follows: by ongoing civil war in Sudan,
2,000,000; by the Khmer Rouge massacre in
Continued on page 6
I've Looked at Clouds
From Both Sides Now...
A unified effort from all who wrestle with
the special issuance process might influence
future FAA funding considerations — a
problem begging for a solution.
BY JACK HASTINGS, MD, PAST-PRESIDENT,
CIVIL AVIATION MEDICAL ASSOCIATION
~V\7"7hen I enthusiastically became an AME
W in 1976, things were different. The
only antihypertensive treatment allowed was
a thiazide diuretic, and the only diabetics
who could fly were those who were controlled
by diet. Now, there are many medications
allowed for hypertension, and several hun-
dred insulin-dependent diabetic pilots are in
the air. Pilots are certified after bypass sur-
gery, stent placement, angioplasty, valve re-
placement, organ transplant, and numerous
other conditions. Continued on page 7
Mini-Photo Album
CAMA Annual
Meeting in
Amsterdam
Photos by M. Young
Stokes, III, MD
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THE
PRESIDENT'S THOUGHTS
BY ROBIN E. DODGE, MD
CAMA's 2003 Activities and Initiatives
• Improve educational resources
• Annual scientific meeting
• 'CAMA Sunday' at AsMA
• Strategic planning event
• Input from members on CAMA structure
I t is now the new year and I ampleased ro report that CAMAhad a very good 2002. Most
activities undertaken last year were
completed successfully.
There are a few items that are
still ongoing such as improving the
FlightPhysician, identifying ways to
be a better educational resource for
members, and reviewing our Con-
stitution and Bylaws.
After the great annual meeting
we had in Amsterdam, the Execu-
tive Board met in Dallas in early
December to review the various
initiatives and to program the new
initiatives for 2003.
So as 2003 begins, CAMA is
busy with its activities and initia-
tives. The next annual scientific
meeting will be held in Seattle in
October and is in the advanced
planning stages.
The main topics currently under
consideration include fatigue, sleep,
SSRIs, and ADHD, in addition to
the customary FAA-related topics
covering AMCD updates, a panel
discussion of cases, and the Federal
Air Surgeon's perspective on current
and future aviation medicine devel-
opments.
Stay tuned: When the agenda is
finalized, we will announce it with-
out delay, so as to give you suffi-
cient time to plan your travel ar-
rangements.
However, even before the Seattle
meeting rolls around, there will be
the second annual "CAMA Sun-
day" at the Aerospace Medical As-
sociation meeting in San Antonio,
Texas, on May 4th, 2003. The plan-
ers are putting together a very ex-
citing program dealing with in-air
medical events centered around the
idea of the doctor as a passenger.
If you are going to San Antonio,
plan on attending the CAMA Sun-
day event. The exact time and place
will be made known in a later
FlightPhysician and posted on the
CAMA Web site.
We are also looking at the po-
tential for a strategic planning event
later this year. I mention this now
to both inform you, the member-
ship, and to solicit your input into
the earliest stages of planning for
such an event.
This is the time for you to let us
know your feelings on anything
dealing with CAMA. How can the
Executive serve you better? What
kind of educational activity do you
want CAMA to provide for you? If
you do not attend the annual meet-
ings—why? What would entice you
to attend an annual meeting—at
least periodically? What if any
changes would you like to see in
the CAMA structure and why?
These are just a few sample ques-
tions to stimulate your thinking.
The Executive is genuinely inter-
ested in your input.
Have a Happy New Year.
January 2003
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Is the Male Pilot
Domain Doomed?
EDITORIAL BY JAMES R. ALMAND, MD
There is today still a strong differ-ence in life expectancy favoring
the female gender. Abundant diverse
options are expressed, but the fact re-
vealed in recent articles is that men "are
in danger of extinction." Due to a num-
ber of past and predictable factors, men
fail to respect "preventive strategies."
The male gender exhibits increased
drug and alcohol abuse, abusive life
styles, stronger mid-life crises, domes-
tic violence, and are, to the largest
part, responsible for all wars and con-
flicts. Violence and homosexuality are
largely male problems. Is there any
evidence that this shorter-lived and
more violent male will eventually re-
cover the life expectancy difference
with his sisters? Not to date, or any
date prior.
Is there a "male proofing" move-
ment afoot to aid the males plight?
Perhaps, though science and technol-
ogy is forging ahead full bore to aid
the "weaker sex" in quality of life and
longevity, leaving her brothers on the
side without only a tiny drop of HRT
research. Some attempts are in place
to increase the males' protection
against "aging," but the lack of medi-
cal specialties promoting male aging
health issues is alarming. All the sci-
ence in longevity today is directed
firmly toward the female. Can the
universe survive with only women?
Clearly, but male-debatable, women
perform well and equally in aviation,
as both crew members and cabin man-
agers. In the entire aviation industry,
females comprise approximately 38%
of the work force and, since emanci-
pation (and WW II), have needed no
proof of their capability.
"Male-Proofing" Movement Needed
Some sources relate that the female
may eventually fall (or swing) to the
same forces that today, historically,
have caused the male downfall in lon-
gevity, but only the future can relate
to this vagary. Even today, your medi-
cal class is 50% female, a sharp increase
from the 1% of 50 years ago. More fe-
males, more equality, more acceptance,
more presence in jobs previously
awarded only to the male is the estab-
lished trend.
What will our Baby Boomer surge
of today's population roll over into the
question of longevity? Will the in-
creased percentage of diseases of the
older generations more level the play-
ing field with men? Probably not, con-
sidering the heavy emphasis science and
pharmacology have on keeping the fe-
male healthy! And this was begun by
male scientists!
Are there any other questions on the
future of the male species? You bet!!
Look at sperm banks, in vitro fertiliza-
tions, genetic manipulation of em-
bryos, somatic egg fertilization, clon-
ing — just as a start!
The questions to be placed here are
not related to the superiority of any sex,
or survival compared to the other, but
how to keep all individuals healthy and
productive to any future "older" age.
Answers lie in today's new scientists,
the Nobel Prize winners who are surg-
ing ahead in genetic and newer scien-
tific fields to reach a goal of disease
control and prolongation of aging. Our
hats are off to them.
Can the universe survive with only
women? Ask them! (see next issue:
2050.)
Reference
5A//323:1013- November 3, 2001
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Facts and Ideas from page i
1975 to 1978 in Cambodia,
1,700,000; by the ongoing war in
Congo, 1,700,000; by US secret
bombings in 1970 to 1973 in
Cambodia, 150,000; by pesticide
suicides of despairing farmers in
China, 125,000; by 2 atomic bombs
dropped by US planes in 1945 in Ja-
pan, 103,000; by obesity in the
United Kingdom, 30,000; by the
Bhopal chemical spill in 1985 and
its aftermath in India, 20,000; by
venomous snakes in India, 10,000;
by malaria in Brazil, 8000; and by
Serbian army massacres of Bosnian
Muslim prisoners, 7000.
Infections
If you want to get frightened, I
suggest Madeline Drexler's new book,
Secret Agents. The Menace of Emerg-
ing Infections (2). She begins this way:
"Infection is an inescapable part of
life. All creatures feast on other crea-
tures and in time are feasted upon in
a kind of Escheresque food chain.
When humans are the meal, we call
it infectious disease." The book is
about today's new and emerging in-
fections—those that have increased
in attack rate or geographic range or
have threatened to do so. It explores
why these infections are materializ-
ing now and why they will never go
away. Each chapter looks at a differ-
ent threat: animal- and insect-borne
diseases, foodborne pathogens, anti-
biotic resistance, pandemic influenza,
infectious causes of chronic disease,
and bioterrorism.
Early on she quotes the famous
bacteriologist and historian, Hans
Zinsser, who wrote in 1934: "How-
ever secure and well-regulated civi-
lized life may become, bacteria, pro-
tozoa, viruses, infected fleas, lice,
ticks, mosquitoes, and bedbugs will
always lurk in the shadows ready to
pounce when neglect, poverty, fam-
ine, or war lets down the defenses.
And even in normal times they prey
on the weak, the very young, and the
very old, living along with us, in
mysterious obscurity waiting their
opportunities."
Drexler describes the swine food
debacle of February 1976, when the
US government pulled out all stops
preparing for a repeat—which never
occurred—of the deadly 1918 influ-
enza pandemic. The summer of 1976
brought legionnaires' disease, which
struck in Philadelphia, killed 34
people, and stumped the infectious
disease experts for nearly 6 months.
Other outbreaks followed and a new
vocabulary arose: Lyme disease, toxic
shock syndrome, Escherichia coli
O157:H7, sexually transmitted dis-
eases, Ebola virus. In June 1981,
came the now landmark report from
the Centers for Disease Control and
Prevention (CDC). Nine brief para-
graphs described a strange cluster of
fatal symptoms among 5 gay men in
Los Angeles: AIDS, which has al-
ready infected 250,000 persons in the
USA. Before the recent headline ac-
counts of avian flu, a silent hepatitis
C epidemic, parasite-contaminated
water slides, new-variant Creutzfeldt-
Jakob disease, and anthrax, we had
smallpox, typhus, polio, cholera, ra-
bies, and the Black Death. We still
have them. None have been con-
signed to history. Small human popu-
lations suffer the oldest diseases of
humankind: either chronic, such as
leprosy or herpes, or those that have
reservoirs in animals or in soil, such
as yellow fever, the virus of which
circulates in monkeys. Only when a
community is dense and filthy
enough to keep spreading germs and
big enough to keep supplying new
susceptibles do such infections as
measles, smallpox, typhoid, and in-
fluenza—crowd diseases or
"zymotics"—stay in circulation.
And the "plagues" of history are
still with us. In AD 79, an outbreak
believed to be malaria contributed to
the Roman Empire's fall. The plague
of Antoninus (AD 166—180), prob-
ably smallpox, killed about 30% of
Italy's population. The plague of Jus-
tinian (AD 542—543), one of the first
documented cases of rat-borne bu-
bonic plague, killed 10,000 people
daily in Constantinople and eventu-
ally spread as far north as Denmark,
annihilating much of the human race
in its path. Between 1346 and 1350,
one third of Europe's population died
of bubonic plague, spread from Asia
to Europe by Mongol armies, whose
retinues of rodents carried infected
fleas that subsequently bit humans.
In the 16th and 17th centuries, slave
ships from West Africa brought yel-
low fever and its mosquito vector to
the New World. Smallpox, trans-
ported to the Americas by Spanish
conquistadors, killed one third of the
relatively disease-free native popula-
tion and was followed by a similar
lethal onslaught of measles. Diseases
introduced from Europe killed an
estimated 95% of the pre-Columbian
Native American population, and
exotic infections attacked the other
direction also. European colonials
succumbed to malaria, yellow fever,
and other endemic infections in
tropical Africa, India, Southeast Asia,
and New Guinea. Syphilis appeared
in 1494, perhaps with Columbus' re-
turning soldiers. The industrial revo-
lution of the 19th century amplified
such diseases as tuberculosis, an an-
cient bacterial infection that thrives
in squalid close quarters. Illnesses
from contaminated food and water,
such as typhoid fever and cholera,
also went on a spree.
Beginning in the late 1870s, the
new discipline of bacteriology found
Continued —>
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the agents that caused cholera, tuber-
culosis, gonorrhea, typhoid, and scar-
let fever. By 1900, most scientists
agreed that microorganisms—spread
by casual contact, food and water
contamination, insects, and even (in
the cases of typhoid and tuberculo-
sis) healthy human carriers—caused
communicable diseases. These dis-
coveries spurred expansion of govern-
ment health initiatives such as water
purification, food inspection, and ro-
dent control, as well as more aware-
ness of individual hygiene measures
such as covering a cough or washing
hands before eating.
In the later 1930s and 1940s,
came specific antimicrobial therapies
such as sulfa compounds and peni-
cillin, and by the mid 1960s numer-
ous antibiotics were available to treat
such infections as gonorrhea, syphi-
lis, pneumonia, tuberculosis, bacte-
rial meningitis, typhoid fever, and
even bubonic plaque, while new vac-
cines prevented epidemics of measles,
rubella, and polio. The study of in-
fectious disease became unfashion-
able between 1970 and 1975. The
National Institutes of Health (NIH)
budget increased 100%, but the bud-
get for infectious diseases increased
only 30%. Cancer and heart disease
got most of the money. When HIV
came along in the early 1980s, the
government initially looked the other
way. Public health agencies had al-
ready stopped surveillance for drug-
resistant tuberculosis just as the dis-
ease started to rise. In the 1980s and
1990s, the US infectious disease
mortality rate jumped 58% even af-
ter removing AIDS from the tally
during that period, and infectious
disease deaths in the USA rose 22%.
In 1998, the CDC issued a detailed
5-year plan to prepare the nation for
emerging infections, but congres-
sional funding has lagged.
And microorganisms (viruses,
bacteria, fungi, protozoa) play the
survival game exceedingly well.
They adapt far more quickly than
do humans as the environment
changes. Humans produce a new
generation every 20 years or so; bac-
teria do it every 30 minutes, and
viruses even faster. Natural selec-
tion, whereby genetically better
adapted individuals leave more
progeny and thus transmit those
desirable characteristics, operates far
more efficiently in the microbial
world. Because they assemble in
enormous numbers, viruses and
bacteria can support considerable
variety in their communities, in-
cluding mutated oddballs that fur-
ther proliferate when circumstances
change. When an enterovirus like
polio goes through the human in-
testinal tract in 3 days, its genome
mutates about 2%. That level of
mutation—2% of the genome—
takes the human species 8 million
years to accomplish!
Compared with humans, micro-
organisms are relatively simple. A vi-
rus (the word comes from a Latin
term for "poisonous substance") is
nothing more than nucleic acid,
DNA or RNA, surrounded by a shell
of protein and sometimes lipids. Vi-
ruses range in size from about 20 to
400 nanometers in diameter, such
that millions can fit in a period at
the end of a sentence. Outside a liv-
ing cell, a virus is a dormant particle,
lacking the raw materials for synthe-
sis. Only when it enters a congenial
host cell does it explode into action,
hijacking the cell's metabolic machin-
ery to produce copies of itself that
may burst out of infected cells or sim-
ply bud off a cell membrane. Viruses
cannot be cultured in artificial me-
dia. They can be propagated only in
live cells, fertilized eggs, tissue cul-
tures, or bacteria. Viruses hurt us by
killing the host cells. Viral infections
are harder to fight once the process
is under way because our immune
responses usually kick in too late to
subdue them.
Bacteria, one-celled organisms
that are more self-sufficient, are about
1000 times larger than viruses and
are generally visible under a light
microscope. Bacteria are known as
prokaryotic—so primitive they lack
a membrane-bound nucleus with
neatly linear chromosomes inside.
Instead, bacteria usually carry a
tangled necklace of DNA joined at
the ends and sometimes smaller rings
of DNA known as plasmids, which
contain genes that enable them to
manufacture proteins. Bacteria carry
only 1 set of chromosomes instead
of 2, an arrangement that means that
every gene counts and every selected
advantage must be conserved.
Over eons, bacteria have learned
tricks to help them cleave to cells,
make paralyzing poisons, allude or
suppress our bodies' defenses, and
shrug off drugs and antibodies. They
pick up genes from almost every-
where: from other bacteria, viruses,
plants, and even from yeast. When a
virus picked up a toxic gene from a
deadly Shigella dysenteriae and in-
serted it into a harmless E. coli, it
created E. coli O157:H7, a bacterial
hybrid that clings to mucosal surfaces
in the intestine and produces toxins
that trigger hemolytic uremic syn-
drome, the most common cause of
acute kidney failure in children. Bac-
teria inflict damage in a different way
than viruses. Sometimes they multi-
ply so rapidly they crowd out host
tissues and disrupt normal function.
Sometimes they kill cells and tissues
outright. Sometimes they manufac-
ture toxins that can paralyze, destroy
metabolic pathways, or generate a
massive immune reaction that is it-
Continued —»
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self toxic. Drug-resistant bacteria
often make an enzyme that destroys
antibiotics or spits them out. Bacte-
ria don't attack until their numbers
are high enough to establish an in-
fection ("quorum sensing"). Never-
theless, bacteria remain easier to treat
than viruses. Because they are free liv-
ing and because their structure dif-
fers from that of mammalian cells,
they are more susceptible to drugs
delivered via the bloodstream.
The newly discovered infectious
agents such as bovine spongiform
encephalopathy (BSE or mad cow
disease)—and its human counter-
part, new-variant Creutzfeldt-Jakob
disease—apparently repealed the laws
of biology. Called prions, these pro-
teins are folded in an unusual way:
When they come into contact with
other proteins, they turn them into
prions, setting off a chain reaction
that eventually riddles the brain with
holes. A cow can contract BSE by
eating 1 g of prion-infected tissue—
the size of a peppercorn—from an-
other cow. Unlike virus or bacteria,
prions cannot reproduce and evoke
no immune response. More fright-
ening, they resist heat, ultraviolet
light, radiation, and sterilization.
Traditional wisdom about emerg-
ing pathogens is that they are nox-
ious because they are new and there-
fore ill adapted to a human host.
Animal viruses, such as the Ebola
virus or the Sin Nombre virus that
causes hantavirus pulmonary syn-
drome, can trigger unusual symp-
toms because our immune response
has not evolved with the virus. Over
the long haul, microorganisms in
humans usually reach a subtle accom-
modation. Humans acquire resis-
tance to the infectious agent while
the parasite becomes milder, permit-
ting us to survive its assault and per-
mitting it to transmit its genes to
someone else. Microorganisms need
their host to survive: A dead host is a
dead end. The reason the lethal spore-
forming bacillus Clostridium botuli-
num—the cause of botulism—has
not leveled our species is that when
it kills us with its toxins, it kills its
prospect for spread.
In the case of emerging infections,
the collision is between pathogens
and people. Emerging infections
come because change is everywhere,
not only for humans but also for
nonhuman animals, plants, seeds,
and insects. Virtually every aspect of
American culture—from where we
live to where we play, from how we
raise livestock to how we raise chil-
dren—is changing, and change cre-
ates new markets, so to speak, for
pathogens, which have a knack for
leveraging the slimmest advantage.
Every day, >2 million people world-
wide cross national borders; every
year, > 1.5 billion people travel by air.
The USA hosts 47 million visitors
yearly. With air travel today, people
in India are like neighbors. Just as in
the 19th century when cholera trav-
eled on steamships to Europe and
Africa, so in the early 1990s cholera
reached the oyster beds of Mobile Bay
by stowing away in the bilge water
of ships from Latin America. Trucks,
freighters, and airplanes have replaced
caravans and steamships. Our stores
are now filled with foods from all over
the world. Any pathogen, not just
those present in food, can be virtu-
ally anywhere in the world within 48
hours. Lyme disease came to us cour-
tesy of 19th-century deforestation in
the Northeast, followed by patchy
and less-diversified second-growth
forests. Coastal population growth
has led to contamination of shellfish
beds with human waste, fostering the
transmission of viral and bacterial
pathogens. Human encroachment on
the tropical rain forest may open the
way for hemorrhagic fever viruses
and perhaps even HIV's mysterious
retroviral cousins.
Communing with nature is not
the only path to pathogens: microbes
also love crowds. In 1900, only 5%
of the world's population lived in cit-
ies with > 100,000 residents. By 2025,
65% of the population in develop-
ing regions will inhabit cities. Dense
urban enclaves are magnets for in-
fections from isolated rural areas and
launchpads that allow pathogens to
reach other fast-growing populations.
Overwhelmed by unsafe water, poor
sanitation, and widespread poverty,
tomorrow's megacities will become
cauldrons for new infections. The
devastating 1998-1999 Nipah virus
outbreak in Malaysia that killed
nearly a third of infected people prob-
ably sprang from intensive pig rais-
ing, which permitted a novel virus
(probably carried by fruit bats) to
propagate and then jump to farm-
ers. Pig farms thus acted as megacities
for the deadly agent, and pig farmers
became sentinel cases. In industrial-
ized countries, day care centers are
notably noxious setting in which the
combination of frequent infections,
susceptible children, poor hygiene,
and high antimicrobial use breeds
diarrheal diseases and antibiotic-re-
sistant microbes.
Keeping ourselves alive longer also
increases our susceptibility to infec-
tion. In 1900, only 4% of the US
population was over age 65; in 2040,
it will reach almost 25%. Elderly in-
dividuals, with their fading immu-
nity, are at the mercy of microorgan-
isms that are normally benign. While
chemotherapy and other immuno-
suppressive treatments have enabled
people to live with cancer and other
illnesses, they also increase our sus-
ceptibility to ubiquitous pathogens
Continued on page 13
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Clouds from page 1
I commend the Office of Aero-
space Medicine for its forward-
thinking approach and dedication
to liberalize certification policy
when advances in medical science
can assure that aviation safety will
not be compromised.
Along with a more liberal certi-
fication policy come greater num-
bers of special issuance cases, or
what I call "problem aeromedical
certification" cases. Included in the
annual influx of more than 450,000
applications for an airman medical
certificate are 6000 or more special
issuance cases that must be re-
viewed. Some are handled by indi-
vidual physician reviewers and oth-
ers by a physician panel at the Aero-
space Medical Certification Divi-
sion (AMCD) in Oklahoma City.
Some are referred to the Office of
Aerospace Medicine in Washing-
ton, and others are sent to indi-
vidual consultants or presented to
a panel of consultants.
When insulin-dependent diabet-
ics were allowed to fly, more work
was created for those in the
AMCD. I understand it takes a
considerable period of time to re-
view the required periodic data.
In parallel with increasingly lib-
eral certification policy through the
years, there were other develop-
ments. Budget cuts, hiring freezes,
early-retirement options, and other
circumstances (currently, increased
funding needs for security) did not
allow the AMCD to keep pace with
the burden of special issuance cases,
and backlogs developed.
The AMCD folks have worked
hard to reduce the backlog and have
succeeded in reducing it to a small
number, only to see it rise again
whenever a snag develops.
The backlog and resultant (of-
ten lengthy) delays in the certifica-
tion process frustrate everyone: the
pilot, the AME, leadership of avia-
tion organizations representing
pilots, and the folks at AMCD
who are trying to achieve timely
certification.
Modernization of equipment at
AMCD will certainly ease the
burden, but not entirely.
Converting all paper aviator
records to an electronic record
(Document Imaging Workflow Sys-
tem, DIWS) will allow instant ac-
cess to a record from any authorized
computer station at AMCD, in the
Regional Flight Surgeons' offices,
and perhaps other authorized sta-
tions (including an AME's office?).
This should greatly ease the ability
to track a record and determine the
status of the case. When fully
implemented, I think DIWS will
help greatly.
Aviation organizations repre-
senting their member pilots have
tried to address problem aeromedi-
cal certification. The EAA's Infor-
mation Services division, Aero-
medical Advisory Council, and
some 200 volunteer EAA/AME
aeromedical advisors try to assist
pilots with special issuance. The
AOPA medical department, headed
by CAMA member Gary Crump,
works full time towards timely aero-
medical certification for its mem-
bers. The American Bonanza So-
ciety has an active medical advi-
sory program and monthly medi-
cal column devoted to aeromedi-
cal certification.
Physicians working for the Air-
line Pilots Association (ALPA) do
the same. There are fee-for-service
entities such as Virtual Flight Sur-
geons and Pilot Medical Solutions
that work in behalf of clients. Cer-
tain AMEs, some of whom do
many flight physicals per year, have
become very familiar with the spe-
cial issuance process and have
found ways to speed the process.
However, the average AME (who
does perhaps 15-20 flight physicals
per year, mostly on healthy indi-
viduals), does not become very fa-
miliar with the methods to speed
problem aeromedical certification.
The individual pilot, the AME,
the aeromedical arm of an aviation
organization, pilot union physi-
cian, and the fee-for-service entity
must all work through a final com-
mon pathway— the AMCD. The
AMCD has limited capacity to ab-
sorb all of the requests for timely
consideration from these groups, no
matter how well-intentioned and
earnest. I feel these efforts to in-
crease flow through a system with
insufficient capacity represent
somewhat of a "Band-Aid" ap-
proach. We pursue speedy special
issuance for our individual con-
cerned pilot, but we do not resolve
the problem for the majority of pi-
lots who are unfamiliar with prob-
lem aeromedical certification. The
system is overwhelmed, with result-
ant, often lengthy, delays in aero-
medical certification decisions.
I would suggest that the ultimate
solution is to address the root of
the problem—a system with insuf-
ficient capacity to accommodate the
flow of special issuance requests and
a resultant inabili ty to provide
timely aeromedical certification.
The Office of Aerospace Medi-
cine represents a small portion of a
very large FAA budget. I recognize
that current security needs have de-
manded much funding attention.
Yet, I feel that problems with the
special issuance process should
merit consideration.
Along with implementation of
DIWS, the addition of personnel
(physicians and other reviewers)
would allow the AMCD to work
toward the ultimate goal of "same
day certification." Impact on the
ent i re FAA budge t would be
minimal.
At its 2001 meeting, the Aero-
space Medical Association ap-
proved a resolution calling for
attention to the special issuance
Concluded on page 15
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CIVIL AVIATION MEDICAL ASSOCIATION
Sustaining and Corporate Members
The financial resources of individual members alone cannot sustain the Association's pursuit of its broad goals
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STEREO OPTICAL, A TRUSTED NAME IN
VISION SCREENING FOR OVER 50 YEARS.
OPTEC? 2000/2500 VISION TESTER FEATURES
Forehead Rest Pressure Bar
Ensures proper patient position.
(Includes disposable forehead tissues.)
Controlled Lighting
For the most accurate
color vision testing
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Peripheral Test (Optional)
Test vision on a horizontal
plane. Stimuli at 85, 70,
and 55 degrees temporal
and nasal.
Distance/Near Lens Systems
Two separate testing ports
for accurate distance and near testing.
Test at 32 indies for
intermediate testing.*
Lightweight, Portable
Built In handle for easy
transport.
Side Access Doors
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interaction.
Near/Far Point Indicators
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Tiit Activator
Height adjustable to
accommodate all patients.
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SLIDE
SLIDE
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Peripheral Test Slide
Distance Letter Acuity Monocular/Binocular (20/200-20/20)
Pseudoisochromatic Color Perception
Near Letter Acuity Monocular/Binocular (20/100-20/20)
Lateral Phoria (1 Diopter Increments)
Vertical Phoria (1/2 Diopter Increments)
Stereo Depth Perception (400-20 Seconds of Arc)
Fusion
Distance Tumbling "E" Acuity Monocular/Binocular (20/200-20/20)
Tumbling "E" Color Perception
Muscle Balance (Combination Lateral & Vertical Phoria)
Distance Allen Test (20/100-20/30)
* This is a requirement for all airmen over the age of 50.
** These tests are required for F.A.A. vision exam.
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For the relief of the nasal and non-nasal symptoms of seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR)
in patients 12 years of age and older, as well as for the symptomatic relief of pruritus, reduction in the number
of hives, and size of hives, in patients with chronic idiopathic urticaria (CIU) 12 years of age and older
When treating SAR, PAR, and CIU, prescribe...
Powerful relief through the 24th hour
Nonsedating—no precautions regarding activities
requiring mental alertness
Safe for use in seasonal allergic rhinitis patients
with concomitant mild to moderate asthma
No clinically relevant drug interactions or effects on QTC
— In studies with erythromycin, ketoconazole, azithromycin,
fluoxetine, and cimetidine
Neither food nor grapefruit juice affected bioavailability
The FAA medically qualifies pilots and air traffic controllers
using the product under special conditions
In allergic rhinitis, the most commonly reported adverse
events included pharyngitis (4.1%, placebo 2.0%),
dry mouth (3.0%, placebo 1.9%), and fatigue (2.1 %,
placebo 1.2%).
In chronic idiopathic urticaria, the most commonly
reported adverse events included headache
(14%, placebo 13%), nausea (5%, placebo 2%),
and fatigue (5%, placebo 1 %).
(desloratadine)TABgL,
Please see brief summary of Prescribing Information on following page.
CLARINEX®
(desloratadine)
TABLETS
Brief Summary (For full Prescribing Information, see package insert.)
INDICATIONS AND USAGE: Allergic Rhinitis: CLARINEX Tablets 5 mg are indicat-
ed for the relief of the nasal and non-nasal symptoms of allergic rhinitis (seasonal
and perennial) in patients 12 years of age and older.
Chronic Idiopathic Urticaria: CLARINEX Tablets are indicated for the symptomatic
relief of pruritus, reduction in the number of hives, and size of hives, in patients with
chronic idiopathic urticaria 12 years of age and older.
CONTRAINDICATIONS: CLARINEX Tablets 5 mg are contraindicated in patients
who are hypersensitive to this medication or to any of its ingredients, or to lorata-
dine.
PRECAUTIONS: Carcinogenesis, Mutagenesis, Impairment of Fertility: The car-
cinogenic potential of desloratadine was assessed using loratadine studies. In an
18-month study in mice and a 2-year study in rats, loratadine was administered in
the diet at doses up to 40 mg/kg/day in mice (estimated desloratadine and deslor-
atadine metabolite exposures were approximately 3 times the ADC in humans at the
recommended daily oral dose) and 25 mg/kg/day in rats (estimated desloratadine
and desloratadine metabolite exposures were approximately 30 times the AUC in
humans at the recommended daily oral dose). Male mice given 40 mg/kg/day
loratadine had a significantly higher incidence of hepatocellular tumors (combined
adenomas and carcinomas) than concurrent controls. In rats, a significantly higher
incidence of hepatocellular tumors (combined adenomas and carcinomas) was
observed in males given 10 mg/kg/day and in males and females given
25 mg/kg/day. The estimated desloratadine and desloratadine metabolite exposures
of rats given 10 mg/kg of loratadine were approximately 7 times the AUC in humans
at the recommended daily oral dose. The clinical significance of these findings dur-
ing long-term use of desloratadine is not known.
In genotoxicity studies with desloratadine, there was no evidence of genotoxic
potential in a reverse mutation assay (Salmonella/E. coli mammalian microsome
bacterial mutagenicity assay) or in two assays for chromosomal aberrations
(human peripheral blood lymphocyte clastogenicity assay and mouse bone marrow
micronucleus assay].
There was no effect on female fertility in rats at desloratadine doses up to
24 mg/kg/day (estimated desloratadine and desloratadine metabolite exposures were
approximately 130 times the AUC in humans at the recommended daily oral dose). A
male specific decrease in fertility, demonstrated by reduced female conception rates,
decreased sperm numbers and motility, and histopathologic testicular changes,
occurred at an oral desloratadine dose of 12 mg/kg in rats (estimated desloratadine
exposures were approximately 45 times the AUC in humans at the recommended
daily oral dose). Desloratadine had no effect on fertility in rats at an oral dose of 3
mg/kg/day (estimated desloratadine and desloratadine metabolite exposures were
approximately 8 times the AUC in humans at the recommended daily oral dose).
Pregnancy Category C: Desloratadine was not teratogenic in rats at doses up to
48 mg/kg/day (estimated desloratadine and desloratadine metabolite exposures
were approximately 210 times the AUC in humans at the recommended daily oral
dose) or in rabbits at doses up to 60 mg/kg/day (estimated desloratadine exposures
were approximately 230 times the AUC in humans at the recommended daily oral
dose). In a separate study, an increase in pre-implantation loss and a decreased
number of implantations and fetuses were noted in female rats at 24 mg/kg (esti-
mated desloratadine and desloratadine metabolite exposures were approximately
120 times the AUC in humans at the recommended daily oral dose). Reduced body
weight and slow righting reflex were reported in pups at doses of 9 mg/kg/day or
greater (estimated desloratadine and desloratadine metabolite exposures were
approximately 50 times or greater than the AUC in humans at the recommended
daily oral dose). Desloratadine had no effect on pup development at an oral dose of
3 mg/kg/day (estimated desloratadine and desloratadine metabolite exposures were
approximately 7 times the AUC in humans at the recommended daily oral dose).
There are, however, no adequate and well-controlled studies in pregnant women.
Because animal reproduction studies are not always predictive of human response,
desloratadine should be used during pregnancy only if clearly needed.
Nursing Mothers: Desloratadine passes into breast milk, therefore a decision
should be made whether to discontinue nursing or to discontinue desloratadine,
taking into account the importance of the drug to the mother.
Pediatric Use: The safety and effectiveness of CLARINEX Tablets in pediatric
patients under 12 years of age have not been established.
Geriatric Use: Clinical studies of desloratadine did not include sufficient numbers
of subjects aged 65 and over to determine whether they respond differently from
younger subjects. Other reported clinical experience has not identified differences
between the elderly and younger patients. In general, dose selection for an elderly
patient should be cautious, reflecting the greater frequency of decreased hepatic,
renal, or cardiac function, and of concomitant disease or other drug therapy, (see
CLINICAL PHARMACOLOGY - Special Populations).
Information for Patients: Patients should be instructed to use CLARINEX Tablets
as directed. As there are no food effects on bioavailability, patients can be instruct-
ed that CLARINEX Tablets may be taken without regard to meals. Patients should
be advised not to increase the dose or dosing frequency as studies have not demon-
strated increased effectiveness at higher doses and somnolence may occur.
ADVERSE REACTIONS: Allergic Rhinitis: In multiple-dose placebo-controlled tri-
als, 2,834 patients received CLARINEX Tablets at doses of 2.5 mg to 20 mg daily,
of whom 1,655 patients received the recommended daily dose of 5 mg. In patients
receiving 5 mg daily, the rate of adverse events was similar between CLARINEX and
placebo-treated patients. The percent of patients who withdrew prematurely due to
adverse events was 2.4% in the CLARINEX group and 2.6% in the placebo group.
There were no serious adverse events in these trials in patients receiving deslor-
atadine. All adverse events that were reported by greater than or equal to 2% of
patients who received the recommended daily dose of CLARINEX Tablets (5.0 mg
once-daily), and that were more common with CLARINEX Tablet than placebo, are
listed in Table 5.
Table 5
Incidence of Adverse Events Reported by > 2% of Allergic Rhinitis
Patients in Placebo-Controlled, Multiple-Dose Clinical Trials
Adverse Experience
CLARINEX Tablets 5 mg Placebo
(n=1j555) M I - 1 . 6 5 k 1 )
Pharyngitis
Dry Mouth
Myalgia
Fatigue
Somnolence
Dysmenorrhea
4.1%
3.0%
2.1%
2.1%
2.1%
2.1%
2.0%
1.9%
1.8%
1.2%
1.8%
1.6%
The frequency and magnitude of laboratory and electrocardiograph^ abnormali-
ties were similar in CLARINEX and placebo-treated patients.
There were no differences in adverse events for subgroups of patients as defined
by gender, age, or race.
Chronic Idiopathic Urticaria: In multiple-dose, placebo-controlled trials of chronic
idiopathic urticaria, 211 patients received CLARINEX Tablets and 205 received
placebo. Adverse events that were reported by greater than or equal to 2% of
patients who received CLARINEX Tablets and that were more common with
CLARINEX than placebo were (rates for CLARINEX and placebo, respectively):
headache (14%, 13%), nausea (5%, 2%), fatigue (5%, 1%), dizziness (4%, 3%),
pharyngitis (3%, 2%), dyspepsia (3%, 1%), and myalgia (3%, 1%).
The following spontaneous adverse events have been reported during the mar-
keting of desloratadine: tachycardia, and rarely hypersensitivity reactions (such as
rash, pruritus, urticaria, edema, dyspnea, and anaphylaxis), and elevated liver
enzymes including bilirubin.
DRUG ABUSE AND DEPENDENCE: There is no information to indicate that abuse
or dependency occurs with CLARINEX Tablets.
OVERDOSAGE: Information regarding acute overdosage is limited to experience
from clinical trials conducted during the development of the CLARINEX product. In
a dose ranging trial, at doses of 10 mg and 20 mg/day somnolence was reported.
Single daily doses of 45 mg were given to normal male and female volunteers for
10 days. All ECGs obtained in this study were manually read in a blinded fashion by
a cardiologist. In CLARINEX-treated subjects, there was an increase in mean heart
rate of 9.2 bpm relative to placebo. The QT interval was corrected for heart rate
(QTC) by both the Bazett and Fridericia methods. Using the QTC (Bazett) there was a
mean increase of 8.1 msec in CLARINEX-treated subjects relative to placebo. Using
QTC (Fridericia) there was a mean increase of 0.4 msec in CLARINEX-treated sub-
jects relative to placebo. No clinically relevant adverse events were reported.
In the event of overdose, consider standard measures to remove any unabsorbed
drug. Symptomatic and supportive treatment is recommended. Desloratadine and
3-hydroxydesloratadine are not eliminated by hemodialysis.
Lethality occurred in rats at oral doses of 250 mg/kg or greater (estimated deslor-
atadine and desloratadine metabolite exposures were approximately 120 times the
AUC in humans at the recommended daily oral dose). The oral median lethal dose
in mice was 353 mg/kg (estimated desloratadine exposures were approximately
290 times the human daily oral dose on a mg/m2 basis). No deaths occurred at oral
doses up to 250 mg/kg in monkeys (estimated desloratadine exposures were
approximately 810 times the human daily oral dose on a mg/m2 basis).
Schering Corporation
Kenilworth, NJ 07033 USA
2/02 23882116T-JBS
U.S. Patent Nos. 4,659,716; 4,863,931; 4,804 666; 5,595,997; and 6,100,274.
Copyright © 2002, Schering Corporation. All rights reserved.
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Facts and Ideas from page 6
Nile virus. And modern technologies
intended to make our lives easier may
also make life easier for microbes. The
bacterium of legionnaires' disease,
which is normally a habitue of moist
soil in lakes, not only thrives in wa-
ter of narrowly warm temperature
ranges, but also must be misted into
tiny particles to penetrate deep into
human lungs—and so is neatly ac-
commodated by cooling towers,
whirlpool spas, and even hot water
pipes. One major worry about organ
transplants from pigs is that these
organs could infect humans with
porcine endogenous retroviruses,
which are in the same class as HIV.
These viruses, which are insinuated
in the donor pig's DNA, could in-
teract with human viruses to create
new, potentially dangerous species
that might spread to the general
population.
Bugs themselves are changing. In
1954, the USA produced 2 million
pounds of antibiotics. Today it makes
tens of millions of pounds per year,
half or more administered to live-
stock. As a result, 70% of bacteria
that cause the infections patients ac-
quire in hospitals are resistant to at
least one antibiotic, and the animals
we eat have become favorites for
drug-resistant microbes. If vancomy-
cin-intermediate Staphylococcus
aureus, or VISA, defies our most
powerful antibiotic, simple scrapes
could become mortal wounds, and
surgery could be as dangerous as it
was 100 years ago. It takes 17 years
to produce a new antibiotic, but a
bacterium can develop resistance in
minutes!
What many biologists fear most
is a new deadly virus. Viruses, of
course, are harder to fight with drugs
and are intimately entangled with the
genes and metabolic machinery in
our cells. Viruses also seem to stimu-
late our immune systems more vio-
lently and self-destructively than do
bacteria. And, unlike with bacteria,
it's harder to predict whether a par-
ticular virus will radiate quickly or
will be especially savage. In the 1930s
during the Great Depression, Hans
Zinsser wrote, "Infectious disease is
one of the few genuine adventures left
in the world. Even the most extreme
sports wouldn't produce the adrena-
line of a race against pandemic in-
fluenza or a cloud of anthrax at the
Super Bowl. In the field of infectious
disease, reality is stranger than any-
thing a writer could dream up. The
most menacing bioterrorist is Mother
Nature herself!"
Madeline Drexler has written a
splendid book!
Smallpox
From 1878 until 1978, when the
virus was eradicated—the first eradi-
cation of an infectious disease—
smallpox killed 1 billion people.
Smallpox is undoubtedly the worst
disease of human beings! If it went
global, smallpox could kill as many
human beings in 15 to 20 weeks as
AIDS has done in 20 years! Small-
pox virus could have been entirely
eliminated from the planet, but that
choice was not made. The World
Health Organization in Geneva,
Switzerland, decided to keep 1 dose
of the vaccine for every 12,000 people
in the world in a freezer. The small-
pox virus now resides officially in only
2 high-security freezers—at the CDC
in Atlanta and at Vector, a Russian
virology institute in Siberia. Today,
smallpox is a weapon of mass destruc-
tion. The virus is alive and it knows
how to make copies of itself in the
human body. Ironically, to keep our-
selves safe from the virus we have to
keep the virus around.
Humans are the only animals who
naturally get smallpox. Researchers
are desperately looking for a nonhu-
man animal to infect with smallpox
so attempts could be made to develop
a smallpox drug. Monkeys are now
being infected with human smallpox!
The Food and Drug Administration
(FDA) requires that any drug or vac-
cine be used in a nonhuman animal
before being tried in a human.
The "demon in the freezer" has
been set loose. It is almost certain that
hostile states including Iraq and
North Korea have illegal stocks of
smallpox. Peter Jahrling, a prominent
biologist, fears that biologists in se-
cret labs are using genetic engineer-
ing to create a new "superpox" virus,
a smallpox virus resistant to vaccines.
One reason for developing an anti-
smallpox drug is that approximately
20% of the US population cannot be
vaccinated: they are immune com-
promised or they have eczema or they
are pregnant women or they are very
young children. That's a large num-
ber of people who will have no pro-
tection if smallpox comes back. That's
why a drug is so important.
These above facts were obtained
from the book The Demon in the
Freezer by Richard Preston (3), who
also wrote The Hot Zone and The
Cobra Event, both New York Times
bestsellers.
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Recent Psychiatric Articles of
Aeromedical Interest
REVIEWED BY DAVID R. JONES, MD, MPH
CONSULTANT IN AEROSPACE PSYCHIATRY
/" • ^Jie December 2002 issue of
the American Journal ofPsy-
^ chiatry has two review ar-
ticles and one editorial with some
aeromedical pertinence. The first
article, "Consultation-liaison psy-
chiatry: contributions to medical
practice," by K.S. Kornfeld (1),
concerns the recognition of a newly
designated sub-specialty, psychoso-
matic medicine, which incorporates
the practice commonly referred to
as "consultation-liaison psychiatry."
An editorial by J.S. Mclntyre (2)
precedes Kornfeld's article and dis-
cusses its place in today's psychiat-
ric and medical domains.
Kornfeld traces the development
and contributions of consultation-
liaison psychiatry to American
medical practice since 1958. Begin-
ning with the clinical observation
that post-operative glaucoma pa-
tients, eye-patched and immobi-
lized, suffered an inordinate inci-
dence of disorientation and de-
lirium (3), psychiatrists went on to
study similar disturbances after
open-heart surgery. This clinical
research led to recognition of the
unfortunately-named "ICU psy-
chosis" syndrome and to wider in-
vestigations into related questions.
These were the opening issues of
this new field.
Why do patients sign out of hos-
pitals against medical advice? (An-
swer: because of anger, anxiety, psy-
chosis, or dementia.)
What are the effects of sleep dep-
rivation while training medical stu-
dents, interns and residents? (An-
swer: about the same as on avia-
tors: nothing good results.)
What should we know about the
psychological needs of cancer pa-
tients, the clinical differentiation in
severely ill patients between "nor-
mal" grief or sadness and clinically
significant depression, and the
question of how much "truth" a
physician should tell their patients,
and when, and how?
Many aspects of modern medi-
cal practice grew out of such inquir-
ies and studies. These investigations
involved not only clinical studies
but also cost-benefit analysis, medi-
cal teaching practices, clinical eth-
ics, clinical genetics and end-of-life
care. Kornfeld tells the story clearly
and well, and his 75 references con-
tain many pearls from the past; e.g.,
Grove's "Taking care of the hateful
patient" (4). Psychosomatic medicine
will soon take its place under the
American Board of Psychiatry and
Neurology as a recognized sub-spe-
cialty alongside child and adoles-
cent psychiatry, geriatric psychiatry,
forensic psychiatry and others.
What has this to do with aero-
medical practice? We flight sur-
geons and aeromedical examiners
interact with our fliers on several
levels. Reading this review article
leads one to think about the com-
plexities involved in adding the
dimension of flying to the physi-
cian-patient relationship. For ex-
ample, we inevitably represent a
threat to flying status or certifica-
tion. When grounding an aviator,
we must deal with the anger and
grief involved in losing flying privi-
leges. Any physician knows some-
thing about the influence of "hate-
ful" personality traits upon the doc-
tor-patient relationship, and other
interactive (transference-counter-
transference) elements that color
everyday medical transactions.
P.G. Nestor's overview of "Men-
tal disorders and violence: person-
ality dimensions and clinical fea-
tures" (5) involves similar general
medical issues. This article exam-
ines the chances of greater risk for
violence (think "air rage") in terms
of our aspect of personality: im-
pulse control, affect (emotional)
regulation, threatened egotism or
narcissism, and paranoid cognitive
style. Nestor considers each of these
elements singly and then discusses
their interactions in patients, crimi-
nals, substance abusers, and others.
His citations of 47 references in-
clude some on behavioral research.
One (6) suggests that "anger in re-
sponse to a narcissistic [ego or self-
esteem] injury is tied to a particu-
lar person and is not a matter of
displacement or leaking out at an
unrelated party." Other research av-
enues are beginning to link observ-
able behavioral pathology with psy-
chological testing instruments and
thence to neurochemical pathways.
"[Tjhe Multidimensional Personal-
ity Questionnaire provides a robust
Continued —>
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measure of impulsivity, which cor-
relates significantly with serotonin
agonist increases in serum prolac-
tin that have been linked to vio-
lence." This questionnaire also pro-
vides information about the man-
agement and modulation of anxi-
ety, anger, hostility and anger. "Failed
affect regulation may lead to lower
thresholds for frustration, agitation,
and irritability, as well as cognitive
and behavioral disorganization."
In an age of emphasis upon
medication as "the answer" to psy-
chiatric questions, review articles
such as these remind us of the larger
aspects of human behavior. Since
psychotropic medications are, for
the most part, disqualifying for
aviation duties, inquiries into non-
pharmacologic mental health thera-
peutics should always interest aero-
medical practitioners.
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A Letter to the Editor
'Our airspace should be enjoyed by all, but certain qualifications need
to be in place...'
(NAME WITHHELD BY REQUEST)
I am a 73-year-old. My driver's
license renewal in Texas was last
month. After a short wait, I filled
out a short questionnaire (epilepsy,
loss of eye or limb, severe diseases,
etc.) and then did a quick visual
test, "stand here on the line for your
photo..." "fingerprint here please,
sign here..." "Your drivers license
will be sent in the mail in a couple
of weeks. It will expire in 2008."
Now really...does that actually
qualify anyone for flight safety, or
perhaps even to walk across the
street? But today the (organization
of which I am a member, the Air-
craft Owners and Pilots Associa-
tion, AOPA) wants me to fly out
of the local airport with some pilot
landing who is flying on a "recre-
ational pilot ticket," [but by the]
way he might have diabetes, hyper-
tension, cardiac disease, or some
other FAA disqualifying disease fly-
ing with only a drivers license as
his medical ticket. To me as a pi-
lot, this is not a question of "free-
dom to fly." "Big brother looking
over your shoulder," or "my rights,"
Clouds from page 7
problem and advocated increased
funding towards a so lu t ion .
CAMA supported the resolution.
The resolution did not result in
any improvement in the system.
Perhaps it is time for a multi-
lateral effort by all those who are
frustrated with the special issu-
ance process. Perhaps a concerted,
but a real question of intelligence
and aviation safety. The question
is not a citizen's right to pilot any
airplane; the question is the safety
of the airspace and the safety of
those who use it.
Our airspace should be enjoyed
by all, but certain qualifications
need to be in place — such as proper
fuel, proper aircraft maintenance,
established altitudes, controlled
landing patterns, biannual flight
review, certification to fly (and
maintain) aircraft and (oh yes)
medical standards! Should a driver's
license enable one to risk the use of
a rented airplane, or your child's life,
or that of a passenger, or risk crash-
ing into a house or into another air-
craft in the pattern or even yet, fly-
ing into a commercial airliner?
The AOPA has a good record of
representation of the general avia-
tion field. However their "driver's
license medical" conception sug-
gests a misconception of their in-
terest of pilots rights. Shouldn't the
pilot be the best-qualified piece of
equipment in his aircraft?
unified initiative by all concerned
might have some influence on
funding considerations for the
AMCD, increasing its capacity to
process special issuance certifica-
tion in a timely manner.
There would be only winners
and no losers. This problem begs
for a solution. FP
FLIGHTPHYSICIAN 16 January 2003
New Members
CAMA welcomes these new members to our growing family of aeromedical colleagues
Ricky L. Artist, MD
1875 Lehigh Street
Boulder, CO 80305-7078
Phone: 303-317-9676
Family Practice AME
Libib Sallam Darwish, MD
P.O. Box 13003
Sana's, Yemen
Phone: 00967-73214342
Surgery AME
Tyrus R. Frerking, DO
7614 S. Goodrich Square
New Albany, OH 43054
Phone: 614-863-1692
Cardiology AME
Philip M. Glencross, MD
PMB# 223, 1427 E. Fienklin
Gastonia, NC 28054
Phone: 704-671-7800
Physical Medicine AME
Kathryn Hamilton, MD
2143 South Branch Road
Somerset, NJ 08876
Phone: 908-369-8871
Family Practice AME
Everett C. Hills, MD
175 Lancaster Blvd.
Mechanicsburg, PA 17055
Phone: 717-691-3755
Physical Medicine Pilot AME
Donald W. Huffman, MD
801 Shady Bluff Trail
Clarksville, TN 37043
Phone: 931-245-8689
Family Practice AME
John G. Jaeger, MD
800 West Avenue South
LaCrosse, WI 54601
Phone: 608-791-9769
Anesthesiology
Jay W. Martin, MD
2195 Allentown Road
Lima, OH 45805
Phone: 419-227-2245
Family Practice
Thomas L. Moore, MD
13117 Eastpoint Park Blvd.
Louisville, KY 40223
Phone: 502-254-0907
Family Practice Pilot
AME
AME
AME
John T. O'Connell, DO
26590 West Taylor Lane
Barrington, IL 60010
Phone: 847-462-0515
Family Practice AME
Odysseas Paxinos, MD
Kifisias 1
N. Iraklio Athens, Greece
Phone: 010-2845429
Orthropaedics Pilot AME
Kennard T. Stradling, MD
511 East 20th Street
Farmington, NM 87401
Phone: 505-566-1915
Occupational Med. AME
Brenda Jo Davies-Wait, DO
P.O. Box 535
Cherry Valley, NY 13320
Phone: 607-364-9468
Internal Med. AME
Conrad R. Zapanta, MD
831 Cantrell Avenue
Harrisonburg, VA 22801
Phone: 540-433-9121
Otolaryneology Pilot AME
CAMA CONSULTANTS
To our new members and as a reminder to all: This is a list of more experienced AMEs that have volunteered to help
with troublesome certification cases. For involved questions, E-mail or fax is preferred. This list is NOT for use by
airmen, but solely for AMEs within the CAMA membership.
Frank H. Austin, MD EST
Phone: 703- 471-1769
Fax: 703-450-3104
E-mail: FHAustin@aol.com
Charles A. Berry, MD CST
Phone: 713-978-7755
Fax: 713-978-5001
E-mail: docchuckb@aol.com
A. Duane Catterson, MD CST
Phone: 281-873-0111
Fax: 281-873-0660
E-mail: cattersib@worldnet.att.net
Marc C. Eidson, MD CST
Phone: 817-599-9472
Fax: 817- 599-9472
E-mail: MARK@EIDSON.ORG
A. J. Parmet, MD CST
Phone: 816-561-3480
Fax: 816-561-4043
E-mail: AJParmet@cysource.com
Gordon L. Ritter, DO MST
Phone: 520-776-9830
Fax: 513-751-5660
E-mail: gordon@rittaire.com
Robert A. Stein, MD EST
Phone: 513-751-0080
Fax: 513-751-5660
E-mail: Bobxtein47@aol.com
M. Young Stokes III, MD CST
Phone 903-465-6707
Fax: 903-465-6744
E-mail: mysiii@flash.net
James L. Tucker, MD EST
Phone: 256-329-7788
E-mail: JLTucker@mindspring.com
Mark Thoman, MD CST
Phone: 515-244-4229
Fax: 515-244-1131
E-mail: PARO1795@aol.com
John D. Hastings, MD CST
Phone: 918-747-7517
Fax: 918-742-7947
E-mail: hastings20@msn.com
H. Stacy Vereen, MD EST
Phone: 404-761-2166
Fax: 404-761-2168
E-mail: Stacyv@earthlink.net
.
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Renesting Syndrome
Phenomenon Often Ruins
Retirement Plans
BY MARK C. EIDSON, MD
In 20 years of family practice, Ihave enjoyed caring for a widerange of patients, from newborns
to the most senior of our citizens. An
increasingly prevalent psychosocial
problem has come to my attention
and deserves notoriety. To address this
problem, I have coined the tern,
"Renesting Syndrome."
Renesting Syndrome is a problem
that seems to reflect our society's
trend. Renesting is when one's
children, grand- or even great-grand-
children, for whatever reason, return
home to live again with the parents,
grand- or great-grandparents. This
return, or "renesting," often thrusts
the previous empty nest home into
financial and psychosocial strain.
Those returning "renesters" often
do so because of a failed marriage,
failed career, or because of drug or
alcohol abuse. There often are minors
involved, requiring care from a re-
sponsible party.
Renesting, although not a new
situation, should be recognized as
a cause of unexpected stress. This,
then, can relate to a variety of prob-
lems for which physicians should
be made more aware.
Antioxidants
BY JAMES R. ALMAND, MD
"Doc, tell me about them oxi-
dants —will they really make me a
STUD?"
"Well, Buddy, the real word is an-
tioxidants, which are advertised to
help your whole body 'get with it.'
"However, for a long time health
nuts talked about buying their pills
to help keep your body 'clean and
active.' They sell plastic bags of 11
vitamin pills to take every morn-
ing with your 7-11 coffee fix. Well,
even today, the big boys, GNC,
Eckerd stores, and druggists (not to
be confused with real pharmacists)
sell millions of these plastic bags for
all suckers and health freaks to buy.
And they make a million dollars off
of you, (like GNC's MegaMan) on
the rumor that all those pills would
cure anything — or help your so-
cial life.
"But listen, lately some of the guys
in the tall towers of the medical
school sniffed it out and said, 'Show
me the proof that your pills fix ev-
erything.' Well now, that has turned
into a problem for the vitamin plas-
tic bag market because the vitamin
proof isn't there.
"So, today, all the GNC and drug-
gist guys are back whittling on the
bench trying to promote a newer
health gimmick to sell or put into
your drinking water."
"Man, Doc. Well, now I guess all
them antioxidants didn't hurt me or
I couldn't eat all this fried chicken
and drink my beer every day, and I'm
sure my cholesterol is OK. Do you
think we should check it? OK, well
now Doc, tell me again. Will those
oxidants help my sex drive or not?"
"Dunno, Buddy. There's no
proof."
"Well, thanks for the poop. Doc,
think I'll go spend the night at my
girlfriend's and take her prenatal vi-
tamins. I'll let you know how they
work — tomorrow."
"See you later."
FP
A call for research involving the
Renesting Syndrome should be in or-
der to help find causes in the appar-
ent surge of this problem. In doing
so, a change in the structure of our
society or family may help prevent
renesting proliferation and ensure
more independent citizens.
If physicians uncover a renesting
event that is adversely affecting their
patients; medical, social and psycho-
logical assistance should be offered.
FP
Dr. Cappelen (I) is
congratulated by Dr. Bird
Dr. Cappelen 2002 Winner
of Bird Award
Per-Johan Cappelen, MD, an
AME for the FAA and the Norwe-
gian Civil Aviation Authority since
1981, was awarded CAMA's Bird
Award at last year's annual meeting
in Amsterdam.
Dr. Cappelen, who lives in
Sandnes, Norway, received CAMA's
highest award for his contributions
to aviation safety through the years
and for his counseling and work with
the 150 helicopter pilots and some
650 technicians who work for
Helicoperservice. In part because of
his dedication to his job, the accident
rate for the company is extremely low.
The Bird Award is given to an in-
dividual who has exhibited excep-
tional service to civil aviation and the
field of aviation medicine.
Visit CAMA's Web Site: www.civilavmed.com
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Mayor's reception for CAMA members.
CAMA's Annual Meeting Photo Album, Volume II
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Relax-
ing with
Bird Award
presentation
Remembering some of the featured speakers at the meeting.
Dr. Dodge
presents a memento
of thanks to a
representative of
the City of
Amsterdam.
Panel members during animated discussion.
IHorizon
FAA Aviation Medical Examiner
Seminar Schedule
2003
March 10-14
April 25-27 _
May 5-8
June 9-13 _
July 18-20
.Oklahoma City, Okla. (Basic)
.Atlanta, Ga. (Ophth/Otolaryn/
Endocrin)
_San Antonio, Texas (Neuro/Psychol/Psy)
.Oklahoma City, Okla. (Basic)
.Chicago, 111. (Aviation Physiology/HF)
August 15 - 17 Washington, D.C./Mclean, Va. (Cardi-
o)
September 15-19_Oklahoma City, Okla. (Basic)
October 3 - 5 Salt Lake City, Utah (Ophth/Otolaryn/
Endocrin)
November 3 - 7 Oklahoma City, Okla. (Basic)
For information, call your regional flight surgeon. To
schedule a seminar, call the FAA Civil Aerospace Medical
Institute AME Programs Office ( 405) 954-4830
CAMA Headquarters
P.O. Box 23864
Oklahoma City, OK 73123-2864
Upcoming Professional Meetings
The Airline Medical Directors Association (AMDA) meets on
Saturday, May 3, 2003.
The Civil Aviation Medical Association (CAMA) will hold a
meeting on Sunday afternoon, May 4, 2003. from 12:30pm to
4:30pm. Everyone is invited to attend; there is no charge for the
meeting. The following is a tentative agenda:
IN-FLIGHT DIVERSIONS, ECONOMIC IMPACT, AIRLINE PERSPECTIVE
David Zanick, MD, Northwest Airlines.
IN-FLIGHT DIVERSIONS DUE TO NEUROLOGIC CONDITIONS
Joseph Sirven, MD, Mayo Clinic, Scottsdale, AZ
INCLUSION OF ANTICONVULSANTS IN AIRLINE MEDICAL KITS
Alex Wolbrink, MD, FAA, Oklahoma City, OK
THE PHYSICIAN AS AN AIRLINE PASSENGER-RESPONDER
Speaker to be announced
TELEMEDICINE
Speaker to be announced
PANEL DISCUSSION/QUESTIONS FOR SPEAKERS
Aerospace Medical Associations Annual Meeting Schedule
May 5-8, 2003: San Antonio, Texas
May 2-6, 2004: Anchorage, Alaska
May 8 — 12, 2005: Kansas City, Missouri
The Board ofTrustees of the Civil Aviation Medical Association wishes to
announce the following annual meeting schedule:
October 8-12, 2003: Seattle, Washington
October 6-10, 2004: Omaha, Nebraska
October 5-9,2005: Charleston, South Carolina,
October 4-8, 2006: Ottawa, Canada,
October 10-14, 2007: San Diego, California
